Merck (MRK) Change in Accured Expenses (2009)
Merck (MRK) reported Change in Accured Expenses of $448.0 million for Q4 2009, up 667.09% on a QoQ basis from -$79.0 million in Q3 2009.
Merck (MRK) has 1 years of Change in Accured Expenses data on file, last reported at $448.0 million in Q4 2009.
- Quarterly Change in Accured Expenses changed N/A year-over-year to $448.0 million in Q4 2009, while the trailing twelve-month figure through Dec 2009 was -$910.0 million (changed N/A YoY) and the FY2025 annual result came in at -$1.8 billion, down 3657.14% from the prior year.
- Change in Accured Expenses rose to $448.0 million in Q4 2009 per MRK's latest filing, from -$79.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $448.0 million in Q4 2009 and bottomed at -$79.0 million in Q3 2009.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | -629.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -1.59 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | -75.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | -702.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -3.50 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | 448.00 Mn |
| Dec 31, 2009 | 448.00 Mn |
| Sep 30, 2009 | -79.00 Mn |
| Sep 30, 2009 | -79.00 Mn |